Storys zum Thema Pharma
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Helsinn grants stendhal rights to Anamorelin, a first-in-class compound to treat cachexia-anorexia related to non-small cell lung cancer (NSCLC)
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
mehrHelsinn at the 31st Annual J.P. Morgan Healthcare Conference, January 8, 2013
Lugano (ots) - Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be ...
mehrPrionics: Favourable assessment of BOVIGAM® tuberculosis test in Europe
Schlieren-Zurich (ots) - The European Food Safety Authority (EFSA) has reviewed field performance data of the BOVIGAM® Interferon-y (IFN-y) test and recommends IFN-y tests for inclusion in the official list of stand-alone tests for bovine tuberculosis (TB). BOVIGAM® is currently widely used as a supplementary test to complement skin testing. Prionics trusts that the ...
mehrPalonosetron infusion bag launched in Japan
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
mehrPrionics: New test to combat scrapie and mad cow disease in sheep and goats
Schlieren-Zurich (ots) - An innovative new test is now available to detect TSE (scrapie and mad cow disease) in sheep and goats. With the Prionics®-Check PrioSTRIP SR, Prionics brings to the market the first test to achieve high diagnostic sensitivity on preclinical TSE cases. The test was approved today by the European Commission for use in TSE testing in small ...
mehrHelsinn Group, Switzerland Announces Support of CancerLinQ / A Rapid Learning System in Oncology Funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology
Lugano (ots) - Helsinn Group announces that it has signed an agreement with the Conquer Cancer Foundation of the American Society of Clinical Oncology to provide long-term financial support for CancerLinQ, a multi-phase initiative to build a rapid learning system in oncology. Helsinn supports the Foundation's ...
mehrPevion launches new immune enhancement platform called Defensomes / Patent already granted in Europe
Ittigen, Switzerland (ots) - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 ...
mehrSequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites
Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites ...
mehrPreclinical Data Support the Potential of AmVacs RSV Vaccine / Innovative approach to the prevention of severe respiratory infections
Zug (ots) - AmVac AG has announced that it has made decisive progress in the development of their new RSV vaccine. The vaccine candidate is based on AmVac's innovative Sendai virus vector platform and developed for the prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus). RSV ...
mehrBINOSTO(TM) - First and Only Buffered Effervescent Solution for the Treatment of Osteoporosis Launched in the USA / EffRx to Regain Rights Outside of North America
Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce that BINOSTO (TM) (alendronate sodium) Effervescent Tablet for buffered oral solution (70 mg) is now available by prescription in the United States. The U.S. Food and Drug Administration earlier this year approved BINOSTO to treat ...
mehrHelsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
Lugano, Switzerland and Melbourne, Australia (ots) - Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist Melbourne biopharmaceutical company Specialised Therapeutics ...
mehrOral Palonosetron shows safe and effective control of nausea and vomiting induced by multiple cycles of chemotherapy
Lugano, Switzerland & Vienna, Austria (ots) - New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor ...
mehrEffRx Names Lorenzo Bosisio Vice President, Head of Business Development and Marketing
Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce and welcome Lorenzo Bosisio, new Head of Business Development and Marketing. Lorenzo will be responsible for the outlicensing and marketing of EffRx's approved product Steovess®/BinostoTM outside of the USA and Canada as well as developing the business for EffRx's other pipeline products. ...
mehrHelsinn Group, Switzerland announces a license agreement for netupitant - palonosetron fixed dose combination with CJ CheilJedang, South Korea for Korea
Lugano (ots) - Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV). The agreement covers the exclusive license and distribution rights for a ...
mehrHelsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
mehrHelsinn partners with the European School of Oncology (ESO)
Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
mehrJan Van Ruymbeke to become new CEO of Daiichi Sankyo Europe / The Belgian executive will replace Reinhard Bauer in October
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end ...
mehrMovianto completes new European Distribution Centre in the Netherlands
Oss, The Netherlands (ots) - Movianto Nederland, the logistics and transportation company specialised in pharmaceuticals and healthcare, is set to begin operations in the new state-of-the- art warehouse especially built to meet the clients' needs. The strategically located warehouse also offers the largest facility for the storage of deep frozen pharmaceutical products ...
mehrWatson to Acquire Actavis Group for EUR 4.25 Billion
Parsippany, NJ (ots) - - Creates 3rd largest global generics company - - ~$8.0 billion anticipated pro forma combined revenue in 2012 - - Significantly increases scale of Watson's ex-U.S. generic business- - Accelerates revenue and earnings growth - - Immediately accretive to non-GAAP earnings, before synergies - - Greater than $300 million annual synergies anticipated within 3 years - - Strong combined cash flow allows ...
mehrPieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting
Chicago, Illinois (ots) - --Results Support Differentiating Drug-like Features for Targeted Anti-cancer Drug-- Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer ...
mehrPevion mandated patient survey confirms disease burden of recurrent vulvovaginal candidiasis (RVVC) and indicates public health problem
Bern, Switzerland (ots) - - - Quality of Life (QoL) is strongly diminished in RVVC patients - Current available treatment fails in two thirds of patients - High medical need demands novel effective treatment options Pevion Biotech AG today announced results from a large, international survey on the Quality of Life ...
mehrPieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin® Program / Grant Supports Personalized Anti-cancer Approach on Path to Clinic
Freising, Germany (ots) - Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a ...
mehrNew Actavis/Bioton alliance to shake up diabetes market / Global managed-care offering to help bring down treatment costs for 366 million diabetics
Warsaw, Poland (ots) - Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin ...
mehrPieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin® Program at ASH Annual Meeting
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today. ...
mehrNHS National Innovation Centre estimates Sequana Medical's ALFApump® System could save the NHS £50 million in ascites care annually
Zurich, Switzerland (ots) - NHS National Innovation Centre supports the cost effectiveness of Sequana Medical's ALFApump System Sequana Medical announced today the findings of an independent economic assessment of the ALFApump System commissioned by the National Innovation Centre, the NHS organization which supports ...
mehrResearch Reveals Upside of CEO Narcissism
Lausanne, Switzerland (ots) - A new study shows self-centered CEOs who "crave acclaim and applause" are more likely to keep their companies at the forefront of technological innovation. Additionally, the desire for attention from self-absorbed CEOs fuels the willingness to make daring decisions that less confident counterparts might shy away from, especially during a period of radical change. Conducted by professors at ...
mehrPieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein ...
mehrPieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin(R) Pipeline Development
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline. ...
mehrEUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia
Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin® ...
mehr